Fmoc-L-Arg(Pbf)-OH is supplied as a pharma-grade protected arginine building block for Fmoc solid-phase peptide synthesis and is not directly blended into tablet, capsule, granule, or injectable formulations. The compound (CAS 154445-77-9, molecular weight 648.76 g/mol) is dissolved in DMF or NMP at 0.2 M working concentration under nitrogen; the free acid form is not water-soluble, and separate solubility data for dichloromethane are limited. In Fmoc-SPPS reactors constructed from glass or 316L stainless steel with a bottom sintered frit and overhead stirring, the Fmoc group is removed with 20% piperidine in DMF using two cycles of 10 minutes each at 20–25°C. Deprotection completion is monitored by UV absorbance at 301 nm from the dibenzofulvene-piperidine adduct. The Pbf side-chain group remains intact under repeated alkaline Fmoc deprotection and is cleaved only during acidolytic release using a mixture of TFA/triisopropylsilane/water 95:2.5:2.5 v/v/v for 2–4 hours. After cleavage, the crude peptide is precipitated in cold methyl tert-butyl ether, dissolved in aqueous acetonitrile, filtered through 0.45 μm membrane filters, and purified on preparative RP-HPLC columns packed with C18 silica. The targeted downstream dosage forms therefore receive a purified, unprotected peptide API manufactured from this monomer, not the monomer itself. For injectable and oral routes, the subsequent API must meet the relevant GMP boundary defined by ICH Q7, ICH Q11, and 21 CFR Part 211. The material is not sterile and is not intended for direct parenteral administration; specifications must be agreed with the contract manufacturing organization before use as a GMP starting material.

What Limits Fmoc Deprotection and Coupling Efficiency in High-Loaded Resins for Injectable Peptide APIs?

In injectable peptide API manufacturing for arginine-containing sequences in GLP-1 receptor agonists and insulin analogues, resin loading above 0.5 mmol/g is a recognized bottleneck because the Pbf-protected guanidine side chain increases steric volume at the coupling site. On a 2 L SPPS reactor with overhead stirrer at 80–120 rpm and nitrogen headspace, a single coupling of Fmoc-L-Arg(Pbf)-OH onto a hindered N-terminal residue frequently produces incomplete acylation. The standard coupling matrix uses 2–4 equivalents of protected amino acid, 1.9–3.8 equivalents of HBTU or HATU, 1.9–3.8 equivalents of HOBt or HOAt, and 4–8 equivalents of DIPEA in DMF. Activation is carried out for 2–3 minutes before transfer to the resin because longer preactivation can form oxazolone intermediates that increase epimerization risk. After 45–90 minutes of coupling at 20–25°C, a positive Kaiser test on the resin indicates free amine; the batch is drained and a second coupling is performed with fresh reagents. Des-Arg truncation is the main impurity risk in this route and must be resolved by preparative HPLC under a gradient of acetonitrile in 0.1% TFA over 40–60 minutes at 2.5–4.0 mL/min per 2 in column diameter. The final injectable peptide API from such syntheses is controlled by LC-MS for the des-Arg and Fmoc residual peptide-related impurities; acceptance is ≤0.5% per individual impurity and ≤1.0% total related substances unless otherwise justified by ICH Q6A. The use of exactly this protected arginine monomer, rather than an unprotected arginine coupling step, avoids guanidino side reactions but introduces the need for complete Pbf removal during cleavage; residual Pbf-containing impurities are monitored by mass spectrometry.

Residual solvents and trace Fmoc-derived impurities in the isolated peptide API govern capsule fill and release. After lyophilization, arginine-containing peptide APIs retain residual DMF, dichloromethane, piperidine, and dibenzofulvene-piperidine adduct until controlled drying. Headspace gas chromatography according to USP <467> must show residual DMF below 880 ppm and dichloromethane below 600 ppm for capsule formulation under ICH Q3C(R8) Class 2 limits. If the API fails, repeated vacuum drying at 35–40°C and 10–15 mbar for 24–48 hours is applied; drying above 45°C is avoided because it can discolor the peptide and increase related peptides. Capsule filling on dosator or tamping-pin machines requires preblending with pharma-grade carriers; lyophilized powder with water content above 2.0% w/w tends to adhere to pins and produce weight variability greater than 3.0% RSD. A dry granulation route is preferred over direct filling because the low bulk density of lyophilized peptide powder complicates slug formation. Roller compaction at 20–40 kN with 0.8 mm screen milling generates dense granules suitable for capsule filling. Enteric HPMC capsules are used for acid-labile peptide APIs rather than gelatin because gastric fluid at pH 1.2 can hydrolyze specific arginine-containing sequences; dissolution testing according to USP <711> uses 0.1 M HCl for 2 hours followed by pH 6.8 phosphate buffer. Release of the capsule product is therefore tied to solvent and moisture data inherited from the upstream amino acid starting material, making a compliant CofA for Fmoc-L-Arg(Pbf)-OH an operational requirement, not an analytical formality.

When Tablet Compression Requires a Milled Peptide Acetate Fraction With Tight Particle Size Control

When an arginine-containing peptide API synthesized with Fmoc-L-Arg(Pbf)-OH is formulated into oral tablets, direct compression of the purified lyophilizate is rarely feasible due to poor flow, electrostatic charging, and high hygroscopicity. The API is converted from trifluoroacetate to acetate salt using strong anion-exchange resin, concentrated by rotary evaporation, and lyophilized. The resulting cake is milled through a 0.5–1.0 mm screen under dry nitrogen with relative humidity below 20%. Particle size distribution is controlled by laser diffraction according to ISO 13320, with D90 target ≤150 μm and D50 40–80 μm. Tablet compression uses a rotary tablet press with 10–20 kN compression force, flat-faced bevel-edge punches of 8 mm diameter, and press speed 20–40 rpm; tablet breaking force is tested according to USP <1217> and is typically maintained at 50–90 N. Wet granulation is avoided because water contact at 40°C can accelerate peptide hydrolysis and increase related peptides; instead, dry blending with mannitol, microcrystalline cellulose, crospovidone, and sodium stearyl fumarate is used. For oral peptide tablets containing salcaprozate sodium as permeation enhancer, the excipient mass can reach 300 mg per tablet, which compresses the API into a small low-dose fraction and demands content uniformity testing according to USP <905> with acceptance value ≤15.0. The central processing risk is moisture uptake above 3.0% w/w causing punch sticking, weight variation, and reduced tablet hardness. Storage of the blend at relative humidity above 60% requires pre-drying at 30°C under 0.1 mbar for 12–24 hours. Actual tensile strength values for arginine-containing peptide acetate formulations are batch-dependent; the operating ranges given here are established from scale-up batch records, and published data for this specific API salt under these exact compression parameters is limited.

Granule and Sachet Manufacturing from Arginine-Containing Peptide APIs for Oral Reconstitution

Granule-based oral dosage forms require a particle agglomeration step that controls water activity and prevents peptide hydrolysis. Arginine-containing peptide APIs obtained from Fmoc-L-Arg(Pbf)-OH-based SPPS are typically converted to acetate or hydrochloride salt and dried to a moisture level below 1.5% w/w by loss on drying before granulation. Fluid bed granulation with aqueous binder is generally unsuitable for these peptides unless the sequence is known to be stable at the selected binder pH and temperature; otherwise dry granulation or organic solvent-assisted spray coating is used. Enteric granules may be coated with Eudragit L 30 D-55 in a fluid bed fitted with a Wurster column at product temperature 25–30°C, spray rate 4–8 g/min per 0.5 kg batch, and triethyl citrate plasticizer at 20% w/w based on polymer dry substance. After coating, granules are dried to water activity 0.3–0.5 and filled into sachets under controlled humidity. Sachet fill weight variation is tested according to Ph. Eur. 2.9.40; a typical limit is ±7.5% for average fill weight below 500 mg. The main batch-failure mode is agglomeration inside the sachet due to residual moisture or static charge, which reduces dispersion in water. This risk is controlled by adjusting the dry-binder content and using hydrophobic silica at 0.1–0.5% w/w to improve flow and stabilize the granule surface.

For injectable dosage forms, the purified peptide API assembled from Fmoc-L-Arg(Pbf)-OH is dissolved in water for injection, pH adjusted to 4.0–5.5 with dilute acetic acid or phosphate buffer, and sterile-filtered through a 0.22 μm polyethersulfone membrane before aseptic filling. The feed solution is tested for bacterial endotoxins using kinetic chromogenic LAL according to USP <85>; the acceptance limit is calculated from the maximum bolus dose, and for high-dose subcutaneous peptide injections it may require ≤0.25 EU/mg. Particulate matter is monitored according to USP <788> by light obscuration; the counts for particles ≥10 μm and ≥25 μm must remain below the compendial limits for the container volume. Lyophilization cycles for 2R or 6R glass vials are run with a primary drying shelf temperature of -25°C and chamber pressure 0.1–0.3 mbar for 24–48 hours, followed by secondary drying at 20–30°C for 6–12 hours. Residual moisture after lyophilization is determined by USP <921> coulometric Karl Fischer; levels above 1.0% w/w reduce long-term peptide stability through hydrolysis of susceptible amide bonds. The injectable route requires removal of TFA counterion before lyophilization because residual trifluoroacetate can acidify the reconstituted solution and raise osmolality; ion exchange to acetate is confirmed by ion chromatography with conductivity detection. Incompatibilities include strong oxidizing agents, pH above 7.0, and prolonged storage in unbuffered aqueous solution at 25°C, which accelerate deamidation of arginine-containing peptide APIs.